HomeCompareSTBFF vs JNJ

STBFF vs JNJ: Dividend Comparison 2026

STBFF yields 2.46% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 STBFF wins by $400.2K in total portfolio value
10 years
STBFF
STBFF
● Live price
2.46%
Share price
$29.00
Annual div
$0.71
5Y div CAGR
60.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$430.5K
Annual income
$251,982.63
Full STBFF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — STBFF vs JNJ

📍 STBFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSTBFFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, STBFF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
STBFF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

STBFF
Annual income on $10K today (after 15% tax)
$209.37/yr
After 10yr DRIP, annual income (after tax)
$214,185.24/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, STBFF beats the other by $210,199.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of STBFF + JNJ for your $10,000?

STBFF: 50%JNJ: 50%
100% JNJ50/50100% STBFF
Portfolio after 10yr
$230.4K
Annual income
$128,336.01/yr
Blended yield
55.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

STBFF
No analyst data
Altman Z
2.7
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

STBFF buys
0
JNJ buys
0
No recent congressional trades found for STBFF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSTBFFJNJ
Forward yield2.46%2.13%
Annual dividend / share$0.71$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR60.4%28%
Portfolio after 10y$430.5K$30.3K
Annual income after 10y$251,982.63$4,689.40
Total dividends collected$391.7K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: STBFF vs JNJ ($10,000, DRIP)

YearSTBFF PortfolioSTBFF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,095$395.09$10,592$272.30+$503.00STBFF
2$12,529$657.13$11,289$357.73+$1.2KSTBFF
3$14,518$1,112.38$12,123$472.89+$2.4KSTBFF
4$17,467$1,932.31$13,141$629.86+$4.3KSTBFF
5$22,174$3,484.95$14,408$846.81+$7.8KSTBFF
6$30,359$6,632.17$16,021$1,151.60+$14.3KSTBFF
7$46,096$13,611.58$18,122$1,588.22+$28.0KSTBFF
8$80,304$30,981.51$20,930$2,228.20+$59.4KSTBFF
9$166,835$80,909.56$24,792$3,191.91+$142.0KSTBFF
10$430,496$251,982.63$30,274$4,689.40+$400.2KSTBFF

STBFF vs JNJ: Complete Analysis 2026

STBFFStock

Suntory Beverage & Food Limited manufactures and sells alcoholic and non-alcoholic beverages and foods in Japan, Europe, rest of Asia, and the Americas. It offers mineral water, coffee drinks, tea drinks, carbonated drinks, sports drinks, and food for specified health uses under various brands. The company was incorporated in 2009 and is headquartered in Tokyo, Japan. Suntory Beverage & Food Limited is a subsidiary of Suntory Holdings Limited.

Full STBFF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this STBFF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

STBFF vs SCHDSTBFF vs JEPISTBFF vs OSTBFF vs KOSTBFF vs MAINSTBFF vs ABBVSTBFF vs MRKSTBFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.